Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy

Supportive Care in Cancer

Volumn 21, Issue 6, 2013, Pages 1561-1568

  Olver, I N ^a   Grimison, P ^b   Chatfield, M ^c   Stockler, M R ^b,c   Toner, G C ^d   Gebski, V ^c   Harrup, R ^e   Underhill, C ^f   Kichenadasse, G ^g   Singhal, N ^h   Davis, I D ⁱ   Boland, A ^c   McDonald, A ^c   Thomson, D ^j  

^a CANCER RESEARCH DIVISION   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL HOBART HOSPITAL   (Australia)

^f Border Medical Oncology Australia   (Australia)

^g FLINDERS UNIVERSITY   (Australia)

^h ROYAL ADELAIDE HOSPITAL   (Australia)

ⁱ LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^j PRINCESS ALEXANDRA HOSPITAL   (Australia)

more..

Author keywords

5 day cisplatin; 5Hydroxytryptamine3 receptor antagonist; Antiemetic; Aprepitant; Dexamethasone; Germ cell tumors

Indexed keywords

APREPITANT; BLEOMYCIN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GRANISETRON; IFOSFAMIDE; TROPISETRON;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; GERM CELL TUMOR; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; RETROPERITONEAL NEOPLASMS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 84879161805     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1696-0     Document Type: Article

References (20)

1. Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, Lewis CR, Levi JA, Boyer MJ, Gurney H, Craft P, Boland AL, Simes RJ, Toner GC (2010) Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst 102:1-10
2. Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293-130
3. Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13:85-96
4. Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P (2011) Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant review and consensus statement. Supportive Care in Cancer 19(Suppl 1):S1-S4
5. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Cark-Snow RA, Esperson BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MJ, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D; ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):232-243
6. Toner GC, Stockler MR, Boyer MJ, Jones M, Thomson DB, Harvey VJ, Olver IN, Dhillon H, McMullen A, Gebski VJ, Levi JA, Simes RJ (2001) Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomized trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357(9258):739-45
7. Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLoed AM, Ladduwahetty T, Keown L, Swain C, Baker R, Cascieri M, Ber E, Metzger J, MacIntyre DE, Hill RG, Hargreaves RJ (1996) Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 35:1121-1129
8. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Juie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 97:3090-3098
9. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, De Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocoll 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119
10. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Scmidt C, Taylor A, Carides AD, Evans JK, Horgan JK (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290-2300
11. McRea JB, Majumbar AK, Goldberg MR, Goldberg MR, Iwamato M, Gargano C, Panebianco DL, Hesny M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA (2003) Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17-24
12. Grimison PS, Thomson DB, Stockler MR, et al. (2011) Accelerated BEP for advanced germ cell tumours: an Australian multicenter phase I/II trial. J Clin Oncol 29 (Suppl; abstr 4561)
13. Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F, Aprepitant Moderately Emetogenic Chemotherapy Study Group (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548-1555
14. Einhorn L, Brames M, Dreicer R, Nichols CR, Cullen MT Jr (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Supportive Care in Cancer 15(11):1293-300
15. Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf H-H, Schmoll H-J (2009) Safety and efficacy of a triple antiemetic combination with the the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 45:1184-1187
16. Molassiotis A, Stricker CT, Eaby B, Velders L, Coventary PA (2008) Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care (Engl) 17:444-453
17. D'Acquisto RW, Tyson LB, Gralla RJ et al (1986) The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5:257
18. Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH (2012) Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group Study. J Clin Oncol 30:3998-4003
19. Hesketh PJ, Wright O, Rosati G, Russo M, Levin J, Lane S, Moiseyenko V, Dube P, Kopp M, Makhson A (2011) Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicentre, randomized, double-blind, active-controlled, two arm parallel group study. Support Care Cancer 20:1471-1478
20. Olver IN (2008) Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Ther Clin Risk Manag 4:1-6